-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that the Levetiracetam tablets of Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group were accepted for the application of imitation 4 types of listing
Data show that Levetiracetam tablets are developed by UCB (UCB) for the treatment of partial seizures (with or without secondary generalized seizures) in adults and children over 4 years of age with epilepsy; for adults And add-on treatment for general tonic-clonic seizures in adolescents over 16 years of age with epilepsy
Sales of Levetiracetam Tablets in Physical Pharmacies in Chinese Cities in Recent Years (Unit: RMB 10,000)
Source: Mi Nei.
According to data from Meinenet, in 2020, the total sales of Levetiracetam tablets in Chinese urban public hospitals, county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 10 100 million yuan, Utimes has the largest market share
Source: Meinenet MED2.
At present, Levetiracetam tablets have 9 manufacturers including Zhejiang Jingxin Pharmaceutical, Zhejiang Prokangyu Pharmaceutical, and Shenzhen Xinlitai Pharmaceutical
In addition, 8 companies have submitted applications for listing for this product and are under review and approval.
Source: CDE official website, Minet.